Fondaparinux Sodium Injection — FDA Drug Shortage

To Be Discontinued — Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)

The FDA lists a drug shortage record for Fondaparinux Sodium Injection (injection) from Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.) with status To Be Discontinued. The shortage was first posted on 09/29/2025.

Shortage Details

Status
To Be Discontinued
Company
Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)
Package NDC
0781-3465-95
Dosage Form
Injection
Presentation
Fondaparinux Sodium, Injection, 7.5 mg/.6 mL (NDC 0781-3465-95)
Initial Posting
09/29/2025
Revised Date